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The subcutaneous and systemic injection of serotonin reduces cutaneous and visceral pain thresholds and increases
responses to noxious stimuli. Different subtypes of 5-hydroxytryptamine (5-HT) receptors are suggested to be
associated with different types of pain responses. Here we show that serotonin also inhibits catechol O-
methyltransferase (COMT), an enzyme that contributes to modultion the perception of pain, via non-competitive
binding to the site bound by catechol substrates with a binding affinity comparable to the binding affinity of
catechol itself (Ki= 44 μM). Using computational modeling, biochemical tests and cellular assays we show that
serotonin actively competes with the methyl donor S-adenosyl-L-methionine (SAM) within the catalytic site. Binding
of serotonin to the catalytic site inhibits the access of SAM, thus preventing methylation of COMT substrates. The
results of in vivo animal studies show that serotonin-induced pain hypersensitivity in mice is reduced by either SAM
pretreatment or by the combined administration of selective antagonists for β2- and β3-adrenergic receptors, which
have been previously shown to mediate COMT-dependent pain signaling. Our results suggest that inhibition of
COMT via serotonin binding contributes to pain hypersensitivity, providing additional strategies for the treatment of
clinical pain conditions.Introduction
Catechol O-methyltransferase (COMT) is an enzyme that
has been implicated in the perception of mechanical, ther-
mal, and inflammatory pain in both humans and rodents
[1–3]. Its association with a broad range of noxious stimuli
suggests its critical role as an underlying factor for the
fundamental processes of pain perception. The enzymatic
activity of COMT is reversely correlated with the intensity
of perceived pain; higher levels of COMT activity corres-
pond to lower pain sensitivity [1–4]. Thus, compounds or
cellular regulatory factors that lower COMT activity en-
hance pain sensation.
While commonly associated with antinociception [5,6],
serotonin (5-hydroxytryptamine, or 5-HT) is also known to
produce a hyperalgesic response when injected subcutane-
ously or into deep tissue [7,8]. Different subtypes of 5-HT
receptors are associated with hypersensitive responses to* Correspondence: dokh@med.unc.edu; luda@unc.edu
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reproduction in any medium, provided the orvarious noxious stimuli. For example, mechanical hypersen-
sitivity (allodynia) induced by serotonin has been linked to
5-HT1A, 5-HT2B, and 5-HT2C receptors [7,9], whereas
the 5-HT2A receptor appears to be responsible for 5-HT-
induced thermal hypersensitivity [10].
A co-factor necessary for methylation of COMT sub-
strates is S-adenosyl-L-methionine (SAM). SAM is respon-
sible for donating the methyl group to a single hydroxyl
group of the catechol substrate. Without SAM, COMT is
unable to metabolize substrates such as norepinephrine and
epinephrine, thereby leading to a potentiation of pain sig-
naling through the downstream stimulation of β2 – and β3–
adrenergic receptor pathways [2]. In comparing the chem-
ical structures of SAM and serotonin (Figure 1A), we noted
that the indole ring of serotonin is similar to the adenosine
motif of SAM. Thus, we hypothesized that serotonin may
play a role as a competitive inhibitor of SAM, which could
provide a novel avenue for COMT-dependent pain modula-
tion. Specifically, the inhibition of COMT activity through
serotonin might reduce the ability of COMT to methylate
endogenous catecholamine substrates, including several
neurotransmitters, such as dopamine, epinephrine, and nor-
epinephrine [11]. Here, we investigate the bindingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 In silico and in vitro binding of serotonin and COMT. (A) Structures of serotonin and S-adenosyl-L-methionine (SAM). (B) SPR data is
fitted to association and dissociation curves to determine the kinetics of serotonin binding (kon = 0.0012 s
-1, koff = 13.7404 M
-1 s-1). (C and D)
Structural modeling of serotonin within COMT active site. (C) Surface representation of serotonin binding to a pocket within COMT. Serotonin
structure is shown in cyan; SAM structure is shown in green. The overlapped structures indicate that the amine sidechain of serotonin prevents
SAM from actually binding to COMT. On the COMT surface, blue represents positively-charged, red represents negatively-charged, and white
represents neutrally-charged regions. (D) Interactions of serotonin with residues inside COMT active site. COMT structure and residues are shown
in green; serotonin is shown in blue. Hydrogen-bonding interactions are highlighted with yellow-dashed lines.
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silico, in vitro, and behavioral studies.
Results
Serotonin Binds to COMT
Binding interactions between serotonin and COMT were
determined through surface plasmon resonance (Figure 1B)
whereby both the rate of association (kon) and dissociation
(koff ) can be determined. We find that serotonin dissociates
from COMT with a koff rate of 0.0012 s
-1, and binds to
COMT with a kon rate of 13.7404 M
-1 s-1. The equilibrium
dissociation constant (KD) was determined by dividing the
dissociation rate from the association rate, and calculated to
be 87 μM.
Serotonin Computationally Docks to the COMT Active Site
Next, we investigated whether serotonin could be
accommodated within the catalytic site of COMT. Using
computational docking tools [12,13], we dock serotonin to
an apo-COMT protein to predict its native pose in theactive site. We find that serotonin occupies a site within the
pocket that sterically overlaps with the binding site of SAM
(Figure 1C). In the crystal structure of holo-COMT, His142
participates in an edge-to-face interaction with the adeno-
sine of SAM [14]. However, during serotonin binding,
His142 donates a hydrogen bond with the amine side chain
of serotonin (Figure 1D). Another hydrogen bonding inter-
action takes place with the serotonin amine and the side
chain carboxyl group of Asp90. These two residues are
responsible for positioning serotonin near the binding
pocket of SAM, thereby preventing SAM from accessing its
site. The carbonyl backbone of His142 also accepts a hydro-
gen bond from the hydroxyl group of serotonin.
Two more residues form hydrogen-bonding interactions
with serotonin. The carbonyl of Met40 forms a hydrogen
bond with the imidazole group of serotonin, while Lys144
forms a hydrogen bond with the hydroxyl group of sero-
tonin. The side chain of Met40 also packs against the in-
dole ring of serotonin. Overall, the results of this docking
simulation suggest that serotonin may inhibit COMT
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SAM.
Serotonin Inhibits COMT Activity
To test whether the binding of serotonin leads to inhibition
of COMT activity, we performed a set of kinetics experi-
ments to measure the reaction rates in either the presence
or the absence of serotonin (Figure 2A,B). We measured
the variance in reaction velocity with respect to changes in
catechol concentration. A double-reciprocal plot comparing
COMT velocities in the presence or absence of serotonin
shows that addition of 100 μM of serotonin decreases the
reaction velocity of COMT (Figure 2C). Thus, serotonin
binding to COMT inhibits COMTactivity.
We examined the kinetics of the observed inhibition in a
set of experiments using a two-site Michaelis-Menten
model (see Materials and Methods; Figure 2D). The
Michaelis-Menten equilibrium constants for catecholFigure 2 Inhibition of COMT with serotonin. (A) and (B) show the react
and presence of 100 μM serotonin, respectively. Legend: 0.5 μM (black), 1 μ
(brown). (C) Lineweaver-Burk plot comparing the reciprocal velocities of ac
(black) and presence (red) of 100 μM serotonin. The higher slope observed
determination of equilibrium inhibition constant. Activity assays in the abse
site Michaelis-Menten model. While the KM for catechol remains relatively t
suggesting a non-competitive mechanism of inhibition between serotoninbinding were determined when serotonin was absent or
present (100 μM) to provide the calculated values or the ap-
parent KM and KM,app (see Materials and Methods). A com-
parison of the calculated KM (16 μM) and KM,app (18.5 μM)
values shows a negligible difference between their affinities
towards the catechol substrate. However, a comparison of
the maximum velocities reveals a greater difference. The
Vmax in the absence of serotonin was 16 nM/min while the
apparent Vmax,app in the presence of serotonin was 7 nM/
min, suggesting that serotonin inhibition is non-competitive
with respect to catechol.
Given the differences between Vmax and Vmax,app, we can
calculate the inhibition constant for serotonin (apparent Ki,
or Ki,app; see Materials and Methods). We find that Ki,app is
44 μM, which is within the vicinity of our approximate KD
determined via SPR (~87 μM). Overall, our results show
that serotonin binds to COMT and inhibits its activity at a
concentration that is similar to endogenous COMTion rates of COMT at different catechol concentrations in the absence
M (red), 3.3 μM (green), 5 μM (blue), 10 μM (orange), 33 μM catechol
tivity against the reciprocal concentration of catechol in the absence
for serotonin indicates some level of inhibition. (D) Michaelis-Menten
nce (black) and presence (red) of 100 μM serotonin were fit to a two-
he same, the Vmax shows some noticeable differences thereby
and catechol.
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reported for dopamine and ~10 μM for norepinephrine)
[15–19].Serotonin-Induced Hypersensitivity is Diminished by
Pretreatment with SAM or β2/3 Antagonists
If serotonin inhibition of COMT occurs through the com-
petitive binding of the active site with SAM to produce
pain hypersensitivity, we would predict that the adminis-
tration of SAM should antagonize serotonin-induced
hypersensitivity. We tested this hypothesis by performing
a series of standard in vivo nociceptive assays in mice
featuring the intraplantar (i.pl.) administration of serotonin
[9]. We chose to use mechanical allodynia to assess the 5-
HT-COMT interaction over the thermal pain, as thermal
hyperalgesia is a far less important clinical symptom than
mechanical allodynia, being observed in a much smaller
percentage of chronic pain patients, being rated as much
less bothersome, and having lower correlations with global
pain ratings [20–22].
Behavioral responsiveness to mechanical stimuli did not
differ between groups prior to pharmacological manipula-
tions, nor after SAM injection alone. I.pl. administration
of serotonin (10 μM in a 20 μL injection volume) pro-
duced robust ipsilateral tactile hypersensitivity (i.e., mech-
anical allodynia) compared to saline (p< 0.001)
(Figure 3A), consistent with previous observations [9]. No
changes in mechanical withdrawal thresholds were
observed in the contralateral hind paw (data not shown).
Mice pretreated with SAM displayed modestly butFigure 3 Reduction of serotonin-induced hypersensitivity by SAM and
withdrawal threshold (g). In both experiments, serotonin (5-HT) was injecte
4–h period. (A) Pretreatment with 80 mg/kg SAM (5-HT + SAM) lowers 5-HT
HT + Saline). SAM alone (Saline + SAM) produced no changes in withdrawal
β3 antagonists, ICI118,551 and SR59230A (5-HT + ICI/SR), reduces 5-HT-induc
alone (Saline + ICI/SR) produced no changes in withdrawal threshold at anysignificantly less serotonin-induced hypersensitivity com-
pared to saline-pretreated mice (Figure 3A; p=0.02).
As an additional approach to examine whether a COMT
is associated with serotonin-induced hypersensitivity, we
determined whether the blockade of downstream receptors
known to mediate COMT–dependent changes diminishes
serotonin-induced hypersensitivity. Since we have previ-
ously shown that low COMTactivity leads to increased pain
sensitivity via a β2/3-adrenergic mechanism, blocking β2 and
β3 adrenergic receptors should reduce the serotonin-
induced hypersensitivity if that sensitivity is COMT-
mediated [2]. Again, serotonin produced robust hypersensi-
tivity compared to saline-treated controls (p< 0.001;
Figure 3B). Consistent with our hypothesis, we find that
relative to serotonin administration alone, co-administration
of ICI118,551 and SR59230A—compounds that respectively
block β2 and β3 adrenergic receptors—significantly reduces
serotonin hypersensitivity (p=0.01; Figure 3B).
Thus, the results of our behavioral experiments are
consistent with our in vitro and in silico results, and
suggest that at least a portion of serotonin-induced
hypersensitivity is mediated by a COMT ! β2/β3 adren-
ergic receptor mechanism. Furthermore, our results indi-
cate that serotonin can actively compete with SAM for
the catalytic site of COMT.Discussion
Biochemical Interactions of Serotonin and COMT
Using binding and activity assays, we show that sero-
tonin interacts with COMT in a manner that inhibitsβ2/β3 antagonism. In all graphs, symbols represent mean± SEM
d into one hind paw and withdrawal thresholds were assessed over a
-induced hypersensitivity compared to saline-pretreated mice (5-
threshold at any time point. (B) Administration of the selective β2 and
ed hypersensitivity compared to saline controls (5-HT + Saline). ICI/SR
time point.
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serotonin is approximately 87 μM, as determined with
surface plasmon resonance experiments. Based on previ-
ous literature, our calculated KD of 87 μM for serotonin
is a reasonable [15–19]. SAM has the lowest KD reported
among COMT ligands, with a KD of 20.2 μM [17]. In
contrast, many common COMT catechol substrates
exhibited dissociation constants in the range of 40 – 400
μM [17]. The higher dissociation constants observed for
COMT substrates is most likely a consequence of its low
substrate specificity. The binding site for catechol is very
solvent accessible and thus can accommodate a large
array of ligands [14]. Although COMT does not methy-
late most phenols or gallols [23], virtually all catechols
are susceptible to methylation including bulkier steroid
compounds. Thus, given a KD for serotonin that is of the
same order of magnitude observed for other known sub-
strates, the interaction between serotonin and COMT is
very plausible within cells that contain COMT.
We also find that the activity of COMT is reduced in
the presence of serotonin, with a Ki of approximately 44
μM. Furthermore, our data suggest that serotonin is a
non-competitive inhibitor with respect to catechol sub-
strates. These results are in line with our structural model
because serotonin occupies a region within the active site
that appears to hinder SAM binding and still allows cat-
echol binding from a steric viewpoint. Moreover, serotonin
does not possess a methyl group to donate that would sub-
stitute for SAM binding.COMT Contributes to Serotonin-Induced Hypersensitivity
Our in silico models and in vitro results suggest that
serotonin is an inhibitor of COMT. However, whether
this inhibition has biological significance cannot be
ascertained from these data alone. Our structural model
suggests that serotonin inhibits COMT activity by ac-
tively competing with SAM at the active site. This mech-
anism is further supported by our kinetics studies. We
performed behavioral experiments to determine if our in
silico model and in vitro data are predictive of in vivo
effects on pain behaviors. Mice pretreated with SAM dis-
played diminishes serotonin-induced mechanical hyper-
sensitivity (Figure 3A). We hypothesize that the
additional SAM produces this attenuation by decreasing
the probability of serotonin occupying the active site of
COMT. The relatively modest anti-allodynic effect is
most likely due to the limited half-life of SAM [24]. The
donating methyl group resides within a sulfonium center
that is unstable due to its cationic charge. In addition,
each SAM molecule can only donate one methyl group
to a substrate. Once methylation occurs, SAM is con-
verts into S-adenosyl-L-homocysteine (SAH). SAH can
further serve as an inhibitor of COMT activity due to thehigh structural similarity to SAM but like serotonin,
SAH is without a methyl donor [25].
SAM is a cofactor that is responsible for many methyla-
tion reactions within the cell. The behavioral effects of
SAM found presently could be non-specific, and not
mediated only by COMT. Thus, we examined whether
serotonin enhances pain sensitivity via the downstream
stimulation of a β2/3-adrenergic receptors as occurs in re-
sponse to the pharmacological inhibition of COMT[2].
Inhibiting COMT, and thereby preventing methylation of
epinephrine and norepinephrine, promotes pain signaling
through the stimulation of β2 and β3 receptors [2]. If sero-
tonin inhibits COMT in vivo, we would thus expect that
the observed increases in pain sensitivity results, at least in
part, from the activation of β2/3 receptors. Consistent with
this view, blockade of β2/3 receptors inhibited serotonin-
induced pain hypersensitivity in mice (Figure 3B).Implications for Serotonin-Induced Hypersensitivity and
SSRIs
Our current results are of potentially substantial clinical
significance. Increasing the bioavailability of serotonin
with selective serotonin reuptake inhibitors (SSRIs) pro-
duces analgesia in some animal models [6,26] and can be
used to treat clinical pain conditions [27,28]. However,
SSRIs show relatively low analgesic efficacy in patients
suffering from persistent pain conditions such as
fibromyalgia, rheumatoid arthritis, and migraines [27]
[29–31] and have not gained widespread use for the
treatment of persistent pain conditions [32–35]. In con-
trast, agents that have greater effects on the inhibition of
norepinephrine relative serotonin reuptake (SNRIs), like
duloxetine and milnacipran, show greater effect sizes and
are more widely used for the treatment of a number of
persistent pain states [36–38].
The clinical analgesic effects of SSRIs are very modest
and do not match the expectations seen in animal mod-
els. Furthermore, several animal studies note a dual role
for serotonin in both analgesia and hypersensitivity,
which appears to be dependent on the model and site of
administration. Thus, the unraveling of the neural
mechanisms that underlie the dual action of serotonin
on pain perception is of importance. Mechanisms pro-
posed to date that explain the dual action of serotonin
primarily involve the activation of different subpopula-
tions of 5-HT receptors that are distributed at different
anatomical locations [7–10]. Our in silico, in vitro and
in vivo results suggest that serotonin’s pain-promoting
effect can also at least in part be attributed to serotonin-
dependent COMT inhibition. This finding opens a new
avenue for increasing the analgesic efficacy of SSRIs by
co-administrating SAMe and/or non-selective beta-
blockers like propranolol.
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While several 5-HT receptors subtypes are known to
contribute to pain perception, we have demonstrated that
5-HT action on COMT activity is another mechanism
underlying 5-HT induced hypersensitivity, through a non-
competitive binding process between SAM and serotonin
at COMT’s catalytic site. Elucidation of the mechanisms of
serotonin-induced hypersensitivity will contribute to the
further understanding of its pharmacodynamics, and may
lead to the future development of new and effective sero-
tonin-based treatments for human pain conditions.Materials and methods
Docking Simulations of Serotonin to COMT Active Site
We employ the MedusaDock package to generate possible
ligand conformations within the protein active site, and
utilize the MedusaScore package to evaluate each conform-
ation generated by MedusaDock [12,13]. MedusaDock
enables flexible docking of both the ligand and the side-
chain amino acids of the protein. We perform all ligand
docking simulations using the crystal structure of human
COMT (PDB: 3BWM) [14].
Prior to all docking simulations, we first stripped all crys-
tallized ligands bound to COMT. Crystallographic waters
that were in the active site were retained for our docking
simulations. We performed 200 docking simulations for
serotonin, where each simulation began with a different
seed number and each conformation generated from a
simulation was subsequently minimized. All conformations
were then ranked according to their free energy value. The
lowest energy structure is determined to be the native pose.Binding Measurements using Surface Plasmon Resonance
Purified COMT protein (derived from porcine liver) and
serotonin ligand were obtained from Sigma-Aldrich. Protein
concentration was verified by performing a BCA assay
(Thermo Scientific). Purified COMT was biotinylated at its
surface lysine residues using EZ-Link NHS-LC-LC Biotin
(Thermo Scientific) at a 1:1 mole ratio of biotinylating re-
agent to protein and subsequently purified using a 1 mL
Sephadex G-25 medium spin column. Biotinylated COMT
was buffered with 10 mM Tris pH 7.4, 1 mM MgCl2, 1 μM
DTTand stored at 4°C until use.
Surface plasmon resonance (SPR) measurements were
conducted at 25°C using a Biacore 2000 instrument with a
previously established protocol [39]. Biotinylated COMT
was first loaded onto a streptavidin-coated flow cell (sensor
chip SA or Biotin CAPture Kit, GE Healthcare) at a flow
rate of 5 μL/min, followed by a buffer flow, introduction of
serotonin (buffered in 10 mM Tris pH 7.4, 1 mM MgCl2, 1
μM DTT), and then a final wash with buffer (10 mM Tris
pH 7.4, 1 mM MgCl2, 1 μM DTT). Here the flow rate was
established at 5 μL/min.The dissociation rate of the serotonin-COMT com-
plex was determined by fitting the dissociation data to
a single-exponential decay.
R ¼ Ro  e−kd t−toð Þ
Here, the response unit from the SPR machine is
denoted as R. Once the dissociation rate is determined,
the association rate of serotonin to COMT can be found
by fitting to the following equation:
R ¼ Req

1 e ka Serotonin½ þkað Þ ttað Þ

Radiolabeled SAM Activity Assay
Activity of COMT was measured through a series of
experiments where the enzyme was incubated with the
substrate catechol (dissolved in H2O, Fisher Scientific)
and S-[methyl-3H]-adenosyl-L-methionine (PerkinElmer,
10.0 Ci/mmol) [40]. Reactions were carried out in a buf-
fer containing 10 mM Tris (pH 7.4), 1 mM MgCl2, and 1
μM DTT with a total reaction volume of 100 μL.
To determine the linear range of the activity assay,
SAM concentration (1 μM) was held constant while
COMT concentration was varied (10 – 80 ng/μL).
Each reaction was placed in a clean PCR tube and
incubated at 37°C for 30 minutes. After incubation,
reactions were terminated by addition of 100 μL of
1 M HCl to each tube. Radiolabeled catechol products
were extracted from the reaction by adding 10 mL of
scintillation fluid (MonoFlow I, National Diagnostics)
and quantified using a scintillation counter. Activities
were normalized for each reaction by performing a
duplicate reaction with the COMT inhibitor, OR-486
(0.5 mg of inhibitor dissolved in 30 μL DMSO and 20
μL of 0.9% saline; OR-486 buffer alone does not in-
hibit reaction), and subtracting its radioactivity. We
found that the linear range was between 10 and
40 ng/μL, and thus for all subsequent experiments we
used a COMT concentration of 20 ng/μL.
Kinetic experiments were performed at a variety of cat-
echol concentrations (0, 0.5, 1, 3.3, 5, 10, and 33 μM) while
maintaining constant SAM (1 μM) and COMT (20 ng/μL)
concentrations. Reactions were set-up for a variety of time
points: 0, 5, 10, 30, 60, and 120 minutes. Each time-point
reaction is incubated at 37°C and then quenched with 1 M
HCl at its specified time point. Products were quantified as
discussed above. Serotonin-inhibition experiments were
conducted for the same catechol concentrations, but with
the addition of 100 μM of serotonin (Sigma) to each
reaction.
Kinetic parameters were determined by first fitting the
data sets to a single-site Michaelis-Menten model (for
reference), followed by a two-site Michaelis-Menten model
v ¼
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Vmax
SAM½  Cat½ 
SAM½  Cat½  þ Km;SAM Cat½  þ Km;Cat þ KD;SAMKm;Cat
 
where catechol is abbreviated as “Cat.” To determine the
mechanism of serotonin-inhibition, we calculated the ap-
parent Ki (Ki,app) of inhibition for both a competitive and
non-competitive inhibitor, and compared which Ki,app
yielded the lowest value. The apparent Ki for a competitive
inhibitor is given by
Ki;app ¼ Km;Cat Serotonin½ Km;app−Km;Cat
where Km,app is the apparent Km,Cat for the serotonin-
inhibited curve. The apparent Ki for a noncompetitive in-




where Vmax,app is the apparent Vmax for the serotonin-
inhibited curve.
Mouse Behavioral Experiments
Subjects were naïve, young adult (6–14 weeks old) outbred
CD-1W (ICR:CrI) mice of both sexes (Charles River,
Boucherville, QC). Animals were housed in groups of 2 to 6
with same-sex littermates, with food (Harlan Teklad 8604)
and tap water available ad lib. Approximately equal num-
bers of male and female mice were used; no sex differences
were noted so data from both sexes were pooled. All proce-
dures followed the guidelines and regulations of the
Canadian Council on Animal Care, and were approved by
the McGill Downtown Animal Care and Use Committee.
Mechanical sensitivity was measured using the auto-
mated von Frey test. Mice were placed in individual trans-
parent Plexiglas cubicles set atop a perforated metal floor
(with 5-mm diameter holes 7 mm apart), and separated
from each other by opaque dividers. Prior to testing, the
mice were habituated to their surroundings for 1 h. A von
Frey fiber with automatically increasing force (Ugo Basile
Dynamic Plantar Aesthesiometer) was applied to the mid-
plantar hind paw. Three separate withdrawal threshold
determinations (on each hind paw) were taken at baseline
(pre-injection) and then averaged. One withdrawal thresh-
old determination (on each hind paw) was taken at every
post-injection time point.
For the SAM pre-treatment study, after measuring
baseline thresholds, mice received i.p. injections of
S- (5’-Adenosyl)-L-methionine chloride (80 mg/kg)
(Sigma), followed, 15 min later, by 20 μl i.pl. injections of
serotonin hydrochloride (10 uM) (Sigma). Mice were
tested at 15, 30, 45, 60, 90, 120, 180 and 240 min follow-
ing the serotonin injection.For the β-adrenergic antagonist study, mice received
20 μL i.pl. injections of serotonin hydrochloride (5 uM),
followed, 15 min later, by i.p. injection of a cocktail of
ICI118,551 (5 mg/kg) and SR59230A (50 mg/kg)
(Tocris). Mice were tested at 15, 30, 45, 60, 90, 120, 180
and 240 min following the antagonist injection.
Pain hypersensitivity was quantified as the area over the
time-threshold curve (post-injection), using the trapezoidal
method.GEE Analysis
We utilize Generalized Estimating Equations (GEE) to
determine whether SAM pretreatment or co-administra-
tion of SR and ICI treatment versus serotonin alone
resulted in significantly different paw withdrawal thresh-
olds [41] across the repeated measurements. The re-
sponse was the repeated measurements of paw
withdrawal threshold at fixed intervals post-administra-
tion of treatment. This model included an intercept and
a binary covariate reflecting treatment status (e.g.,
ICI118,551 and SR59230A treatment versus serotonin
alone) as the only covariate, where parameter estimates
for this covariate can be interpreted as the overall mean
change over measurements in PWT due to treatment.
We assume an AR[1] correlation structure between
repeated measurements, gaussian distribution of the
data, and the identity link. We tested whether the esti-
mate for our binary covariate for treatment was signifi-
cantly different from zero (indicating a significant
change in paw withdrawal threshold due to treatment ef-
fect) using Proc Genmod in SAS version 9.2, and report
p-values from this test. We also report the estimated
mean change in paw withdrawal threshold due to treat-
ment effect ± the standard error of the mean change.Competing interests
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